RwandaTuberculosis profile
Population  2014 11 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.73 (0.51–0.99) 6.4 (4.5–8.7)
Mortality (HIV+TB only) 0.31 (0.21–0.42) 2.7 (1.8–3.7)
Prevalence  (includes HIV+TB) 9.6 (7–13) 85 (61–112)
Incidence  (includes HIV+TB) 7.1 (6.1–8.2) 63 (54–72)
Incidence (HIV+TB only) 1.8 (1.5–2.1) 16 (14–18)
         
Case detection, all forms (%) 81 (71–94)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.4–3.2) 5.1 (1.7–11)
MDR-TB cases among notified pulmonary
TB cases
99 (64–150) 31 (10–70)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 4 003   347
Pulmonary, clinically diagnosed 554   0
Extrapulmonary 857   0
       
Total new and relapse 5 761    
Previously treated, excluding relapses 263    
Total cases notified 6 024    
Among 5 761 new and relapse cases:
338 (6%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 449 (36%) 172 (28%) 4 675
Laboratory-confirmed RR-/MDR-TB cases     82
Patients started on MDR-TB treatment ***     81
TB/HIV 2014 Number (%)
TB patients with known HIV status 5 944 (99)
HIV-positive TB patients 1 497 (25)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 473 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 1 297 (87)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (85) 5 701
Previously treated cases, excluding relapse, registered in 2013 (75) 278
HIV-positive TB cases, all types, registered in 2013 (76) 1 448
RR-/MDR-TB cases started on second-line treatment in 2012 (98) 58
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 1.3
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 16
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 14
% Funded domestically 20%
% Funded internationally 69%
% Unfunded 11%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-02 Data: www.who.int/tb/data